Department of Hematology and Lymphatic Diseases, Harbin Medical University Tumour Hospital, Harbin, 150081, People's Republic of China.
Department of Breast Surgery, Harbin Medical University Tumour Hospital, Harbin, 150081, People's Republic of China.
J Exp Clin Cancer Res. 2019 Nov 12;38(1):465. doi: 10.1186/s13046-019-1428-0.
Long non-coding RNAs (lncRNAs) are tumor-associated biological molecules and have been found to be implicated in the progression of colorectal cancer (CRC). This study aims to examine the effects of lncRNA RP11-468E2.5 and its target genes (STAT5 and STAT6) on the biological activities of CRC cells via the Janus kinase-signal transducer and activator of transcription (JAK/STAT) signaling pathway.
We initially screened the GEO database for differentially expressed lncRNAs related to CRC and then made a prediction of the implicated target genes. Then we collected CRC tissues and adjacent normal tissues from 169 CRC patients. Human CRC HCT116 and SW480 cells were treated with small interference RNA (siRNA) against RP11-468E2.5, AG490 (an inhibitor of the JAK/STAT signaling pathway), or both in combination. Next, we measured the effects of RP11-468E2.5 treatment on cellular activities such as cell viability, cycle distribution and cell apoptosis, and studied interactions among RP11-468E2.5, STAT5/STAT6, and the JAK/STAT signaling pathway. Finally, an in vivo tumor formation assay was performed to observe the effect of RP11-468E2.5 on tumor growth.
The CRC-related gene microarray data showed low expression of RP11-468E2.5 in CRC surgical specimens. However, RP11-468E2.5 was confirmed to target STAT5 and STAT6, which participate in the JAK/STAT signaling pathway. CRC tissues showed lower expression of RP11-468E2.5, higher expression of STAT5, STAT6 and of the cell cycle marker Cyclin D1 (CCND1), compared to the findings in adjacent normal tissues. The treatment of siRNA against RP11-468E2.5 increased expression of JAK2, STAT3, STAT5, STAT6, CCND1 and Bcl-2 along with the extent of STAT3, STAT5 and STAT6 phosphorylation, while lowering expression of P21 and P27. Treatment with AG490 exhibited approximately opposite effects, whereas siRNA against RP11-468E2.5 treatment stimulated CRC cell proliferation and reduced cell apoptosis, while promoting cell cycle entry; AG490 treatment reversed these results.
Altogether, we conclude that up-regulation of RP11-468E2.5 inhibits the JAK/STAT signaling pathway by targeting STAT5 and STAT6, thereby suppressing cell proliferation and promoting cell apoptosis in CRC.
长链非编码 RNA(lncRNA)是与肿瘤相关的生物分子,已被发现与结直肠癌(CRC)的进展有关。本研究旨在通过 Janus 激酶-信号转导和转录激活因子(JAK/STAT)信号通路,研究 lncRNA RP11-468E2.5 及其靶基因(STAT5 和 STAT6)对 CRC 细胞生物学活性的影响。
我们首先从 GEO 数据库中筛选与 CRC 相关的差异表达 lncRNA,然后对涉及的靶基因进行预测。然后,我们从 169 名 CRC 患者中收集 CRC 组织和相邻正常组织。用针对 RP11-468E2.5、AG490(JAK/STAT 信号通路抑制剂)或两者联合的小干扰 RNA(siRNA)处理人 CRC HCT116 和 SW480 细胞。接下来,我们测量了 RP11-468E2.5 处理对细胞活力、细胞周期分布和细胞凋亡等细胞活性的影响,并研究了 RP11-468E2.5、STAT5/STAT6 与 JAK/STAT 信号通路之间的相互作用。最后,进行体内肿瘤形成实验观察 RP11-468E2.5 对肿瘤生长的影响。
CRC 相关基因芯片数据分析显示,CRC 手术标本中 RP11-468E2.5 表达水平较低。然而,RP11-468E2.5 被证实靶向 STAT5 和 STAT6,它们参与 JAK/STAT 信号通路。与相邻正常组织相比,CRC 组织中 RP11-468E2.5 表达较低,STAT5、STAT6 和细胞周期标志物 Cyclin D1(CCND1)表达较高。针对 RP11-468E2.5 的 siRNA 处理增加了 JAK2、STAT3、STAT5、STAT6、CCND1 和 Bcl-2 的表达,同时增加了 STAT3、STAT5 和 STAT6 的磷酸化程度,而降低了 P21 和 P27 的表达。AG490 处理则表现出相反的效果,而针对 RP11-468E2.5 的 siRNA 处理刺激了 CRC 细胞增殖,降低了细胞凋亡,同时促进了细胞周期进入;AG490 处理则逆转了这些结果。
综上所述,我们得出结论,上调 RP11-468E2.5 通过靶向 STAT5 和 STAT6 抑制 JAK/STAT 信号通路,从而抑制 CRC 细胞增殖并促进细胞凋亡。